<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004913</url>
  </required_header>
  <id_info>
    <org_study_id>NU 98X2</org_study_id>
    <secondary_id>NU-98X2</secondary_id>
    <secondary_id>NCI-G00-1707</secondary_id>
    <nct_id>NCT00004913</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Study of Docetaxel Plus 5-FU, Cisplatin and Leucovorin in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating
      patients who have advanced solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose of docetaxel administered in combination
      with cisplatin, fluorouracil, and leucovorin calcium in patients with advanced solid tumors.
      II. Determine the toxicities associated with this combination regimen in this patient
      population. III. Evaluate the clinical response to this combination regimen in these
      patients.

      OUTLINE: This is a dose escalation study of docetaxel and fluorouracil (5-FU). Patients
      receive docetaxel IV over 1 hour on day 1, cisplatin IV over 1 hour on day 2, and leucovorin
      calcium IV immediately followed by 5-FU IV on days 1-5. Treatment repeats every 3 weeks in
      the absence of disease progression. Cohorts of 3-5 patients receive escalating doses of
      docetaxel and 5-FU until the maximum tolerated dose (MTD) is determined. The MTD is defined
      as the dose preceding that at which more than 1 of 3 or 1 of 5 patients experience dose
      limiting toxicity. Patients are followed every 3 months until death.

      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study over 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date type="Actual">May 2002</completion_date>
  <primary_completion_date type="Actual">May 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Diagnosis of advanced solid tumor No lymphomas Measurable disease

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not
        specified Hematopoietic: Neutrophil count at least 1,000/mm3 Platelet count at least
        100,000/mm3 Hepatic: Bilirubin no greater than upper limit of normal (ULN) AND SGOT no
        greater than 2.5 times ULN AND Alkaline phosphatase no greater than ULN OR SGOT no greater
        than ULN AND Alkaline phosphatase no greater than 5 times ULN Renal: Creatinine no greater
        than 2.0 mg/dL Other: No pre-existing peripheral neuropathy greater than grade 2 Not
        pregnant or nursing Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: No more than 2 prior treatments for metastatic disease Biologic
        therapy: Not specified Chemotherapy: No prior high dose (pre transplant) chemotherapy Prior
        paclitaxel allowed Endocrine therapy: Not specified Radiotherapy: No prior pelvic
        radiotherapy Surgery: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Al B. Benson, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>March 15, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2004</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

